Opexa Therapeutics, Inc. (ACER) Stock Rating Lowered by ValuEngine
Opexa Therapeutics, Inc. (NASDAQ:ACER) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.
Opexa Therapeutics (NASDAQ:ACER) opened at 14.90 on Monday. The firm has a 50-day moving average of $10.40 and a 200-day moving average of $8.29. The stock’s market capitalization is $11.01 million. Opexa Therapeutics has a 1-year low of $5.21 and a 1-year high of $45.62.
About Opexa Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.